兆科眼科-B拟与东生华制药于台湾地区共同推进BRIMOCHOL PF的临床导论及未来商业化
ZHAOKE OPHTH-BZHAOKE OPHTH-B(HK:06622) Zhi Tong Cai Jing·2025-12-08 08:57

Core Viewpoint - The company has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL PF in Taiwan [1] Group 1: Partnership Details - The agreement grants Dongshenghua Pharmaceutical exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL PF [1] Group 2: Product Development and Regulatory Status - Tenpoint Therapeutics, the developer of BRIMOCHOL PF, announced that the FDA has accepted the new drug application for the product, with a Prescription Drug User Fee Act (PDUFA) review deadline set for January 28, 2026 [1]